Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Results View source PDF Explain this filing

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.6%Reaction day

₹1725.10

prior close

₹1781.90

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.9%+7.6% vs market

Pharmaceuticals peers, median of 155sector+0.7%+8.9% vs sector

On the reaction day the stock moved 7.6 pts more than Nifty Smallcap 250 and 8.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.5

10m

+3.2

15m

+3.7

30m

+5.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.6+1.9+7.6+0.7+8.9

Next day

+11.5+1.9+9.6-0.1+11.6

+10.7+2.7+7.9+0.9+9.8

+13.0+1.1+12.0+0.5+12.5

+13.6+4.0+9.6+3.0+10.6

+14.8+4.8+10.0+3.3+11.5

+14.5+3.4+11.1+2.0+12.5

15d

+24.2+5.4+18.7+3.6+20.5

+27.5+1.5+25.9-0.9+28.4

+48.7-6.9+55.6-10.9+59.6

+43.2+9.0+34.2+4.3+38.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Acutaas Chemicals Limited has filed its financial results for the period ended December 31, 2025 (Q3 FY26 / 9M FY26) with the stock exchange. The filing covers both the standalone quarter and the year-to-date period under Indian Accounting Standards (Ind AS). The announcement itself only confirms submission; the detailed results with revenue, profit, and segment numbers will be available in the accompanying PDF filed with the exchange.

Likely market impact

This is a routine regulatory filing disclosure and by itself does not move the stock. Investors should review the detailed results PDF for actual revenue, margin, and profit figures to assess earnings performance versus expectations.